US Pharma MarketingThe post FDA clears Glooko’s cloud-based insulin dosing platform appeared first on Medical Device Network.
FDA clears Glooko’s cloud-based insulin dosing platform
Ideating on Glooko’s existing EndoTool system, the cloud-based version is designed to support more scalable deployment across hospital settings. Ideating on Glooko’s existing EndoTool system, the cloud-based version is designed to support more scalable deployment across hospital settings. The global diabetes population is projected to hit 643 million by 2030, as per data from the International Diabetes Federation. Credit: Tada Images / Shutterstock.com Glooko has secured US Food and Drug Administration (FDA) clearance for EndoTool IV Cloud, priming the cloud-based insulin dosing platform for commercialisation across hospital settings. Endotool is a computer software system that supports individualised insulin dosing for…
Ideating on Glooko’s existing EndoTool system, the cloud-based version is designed to support more scalable deployment across hospital settings.
Source: Medical Device Network